Intellia Therapeutics price target lowered to $48 from $60 at Evercore ISI
Evercore ISI lowered the firm’s price target on Intellia Therapeutics (NTLA) to $48 from $60 and keeps an Outperform rating on the shares after ...
Evercore ISI discusses the biggest challenge to their 6800 S&P target for 2025
Julian Emanuel of Evercore ISI says Trump's economic policies will be moderated and influenced by the bond markets. His does not see a significant downturn in the U.S. economy, explaining his S&P500 ...
Nvidia Leads Tech Surge: Evercore ISI Forecasts 22% S&P 500 Growth in 2025
Evercore ISI anticipates a 22% growth in the S&P 500 Index to 7,200, up from its current level of 5,940, therefore signaling ...
Intellia Therapeutics (NTLA) Receives a Buy from Evercore ISI
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price target of ...
Europe’s Automakers Face Pummeling In 2025 But Positives Remain
Europe’s automakers face existential threats from EU CO2 rules, China competition, weak sales and factory closures. The ...
GE HealthCare price target lowered to $98 from $102 at Evercore ISI
Evercore ISI lowered the firm’s price target on GE HealthCare (GEHC) to $98 from $102 and keeps an Outperform rating on the ...
Nasdaq23d
Celanese price target lowered to $85 from $170 at Evercore ISI
Evercore ISI analyst Eric Boyes lowered the firm’s price target on Celanese (CE) to $85 from $170 and keeps an In Line rating on the shares as a new analyst took over coverage of the stock and ...
Evercore ISI Reaffirms Their Buy Rating on Costco (COST)
In a report released today, Greg Melich from Evercore ISI maintained a Buy rating on Costco (COST – Research Report), with a price target of ...